| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights |
| 05 Nov 2026 | SCHEDULE 13G |
| 29 Sep 2026 |
Form 4: Karlin Daniel, Director
Sold 10,853 shares ($397K) |
| 29 Sep 2026 |
Form 4: Barrow Robert, Director
Sold 31,550 shares ($1.15M) |
| 29 Sep 2026 |
Form 4: Wiley Matthew T., Chief Commercial Officer
Sold 3,097 shares ($113K) |
| 29 Sep 2026 |
Form 4: Sullivan Mark, Chief Legal Officer
Sold 14,051 shares ($514K) |
| 29 Sep 2026 |
Form 4: Roberts Brandi, Chief Financial Officer
Sold 3,377 shares ($123K) |
| 25 Sep 2026 | 144 |
| 25 Sep 2026 | 144 |
| 25 Sep 2026 | 144 |
| 25 Sep 2026 | 144 |
| 25 Sep 2026 | 144 |
| 18 Sep 2026 |
Form 4: Vallone Carol A, Director
Received 1,086 shares by exercise or conversion ($38.6K) |
| 18 Sep 2026 |
Form 4: Krebs Andreas, Director
Received 1,629 shares by exercise or conversion ($57.9K) |
| 14 Sep 2026 |
Form 4: Karlin Daniel, Chief Medical Officer
Received 200,000 shares as a grant or award |
| 14 Sep 2026 |
Form 4: Wiley Matthew T., Chief Commercial Officer
Received 125,000 shares as a grant or award |
| 14 Sep 2026 |
Form 4: Sullivan Mark, Chief Legal Officer
Received 125,000 shares as a grant or award |
Loading...